CervoMed Inc. Files 8-K for Regulatory Updates
Ticker: CRVO · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1053691
| Field | Detail |
|---|---|
| Company | Cervomed Inc. (CRVO) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, disclosure
TL;DR
CervoMed filed a routine 8-K on 3/5/24 for disclosures, no major news.
AI Summary
CervoMed Inc. filed an 8-K on March 5, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This filing serves as a standard disclosure for CervoMed Inc., informing the public about regulatory compliance and financial reporting, which is crucial for investor transparency.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and does not appear to contain any new material information that would significantly impact the company's risk profile.
Key Players & Entities
- CervoMed Inc. (company) — Registrant
- 0001053691 (company) — Central Index Key
- 001-37942 (company) — SEC File Number
- 30-0645032 (company) — I.R.S. Employer Identification No.
- 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 (company) — Principal Executive Office Address
- 20160115 (date) — Former Company Name Change Date (Diffusion Pharmaceuticals Inc.)
- 20140307 (date) — Former Company Name Change Date (RestorGenex Corp)
- 20080722 (date) — Former Company Name Change Date (Stratus Media Group, Inc)
FAQ
What is the primary purpose of this 8-K filing by CervoMed Inc.?
The primary purpose of this 8-K filing by CervoMed Inc. is to report on Regulation FD Disclosure and Financial Statements and Exhibits, as indicated in the filing details.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on March 5, 2024.
What is CervoMed Inc.'s principal executive office address?
CervoMed Inc.'s principal executive office is located at 20 Park Plaza, Suite 424, Boston, Massachusetts 02116.
Has CervoMed Inc. undergone previous name changes?
Yes, CervoMed Inc. has undergone previous name changes, including from Diffusion Pharmaceuticals Inc. on January 15, 2016, from RestorGenex Corp on March 7, 2014, and from Stratus Media Group, Inc on July 22, 2008.
What is CervoMed Inc.'s state of incorporation and fiscal year end?
CervoMed Inc. is incorporated in Delaware and its fiscal year ends on December 31.
Filing Stats: 769 words · 3 min read · ~3 pages · Grade level 12.7 · Accepted 2024-03-05 08:51:44
Key Financial Figures
- $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market
Filing Documents
- crvo20240304_8k.htm (8-K) — 32KB
- ex_634722.htm (EX-99.1) — 28KB
- logosml.jpg (GRAPHIC) — 4KB
- 0001437749-24-006546.txt ( ) — 202KB
- crvo-20240305.xsd (EX-101.SCH) — 3KB
- crvo-20240305_def.xml (EX-101.DEF) — 11KB
- crvo-20240305_lab.xml (EX-101.LAB) — 15KB
- crvo-20240305_pre.xml (EX-101.PRE) — 11KB
- crvo20240304_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure Corporate Presentations Certain information concerning the business, clinical studies, development plans, financial position and related matters of CervoMed Inc. (the "Company" or "us") has been made available on our website, www.cervomed.com, under the heading, "Investors – Events and Presentations." Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others. The information contained in the presentation is summary information that is intended to be considered in the context of the Company's filings with the Securities and Exchange Commission ("SEC") and other public announcements that we may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. Press Release On March 5, 2024, we issued a press release announcing the presentation of biomarker data from our previously completed AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies at the 18th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) 2024, being held both virtually and in Lisbon, Portugal, from March 5–9, 2024 A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 (including any informa
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release issued March 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 5, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: General Counsel